Focus Partners Wealth
SMMT icon

Focus Partners Wealth’s Summit Therapeutics SMMT Stock Holding History

Focus Partners Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.48M Buy
170,338
+86,418
+103% +$1.53M ﹤0.01% 1269
2026
Q1 		$1.59M Sell
83,920
-4,528
-5% -$73.2K ﹤0.01% 1416
2025
Q4 		$1.55M Buy
88,448
+29
+0% +$546 ﹤0.01% 1438
2025
Q3 		$1.83M Buy
88,419
+1,979
+2% +$48K ﹤0.01% 1049
2025
Q2 		$1.84M Buy
86,440
+1,965
+2% +$44.8K ﹤0.01% 925
2025
Q1 		$1.63M Buy
84,475
+9
+0% +$181 ﹤0.01% 910
2024
Q4 		$1.51M Hold
84,466
– – ﹤0.01% 929
2024
Q3 		$1.85M Buy
+84,466
New +$1.18M 0.01% 781

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Focus Partners Wealth's SMMT Position: Q2 2026 in Review

Focus Partners Wealth increased its Summit Therapeutics (SMMT) stake by 103% in Q2 2026, buying an estimated $1.53M and bringing the position to 170,338 shares worth $2.48M. The position accounts for ﹤0.01% of the portfolio, ranked #1269.

Focus Partners Wealth first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Focus Partners Wealth held 170,338 shares of Summit Therapeutics worth $2.48M as of Q2 2026.
  • Focus Partners Wealth bought 86,418 Summit Therapeutics shares in Q2 2026, an estimated $1.53M.
  • Summit Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #1269 holding.
  • Focus Partners Wealth first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.